$GNPX

Genprex, Inc.

Genprex is a clinical-stage gene therapy company developing gene-based treatments for cancer and diabetes. Its oncology platform uses the ONCOPREX Delivery System, a systemic, non-viral method that delivers tumor suppressor gene-expressing plasmids to cancer cells. Its lead candidate, REQORSA Gene Therapy, is being developed in combination with approved cancer drugs for non-small cell and small cell lung cancers. Genprex also has preclinical diabetes candidate GPX-002, based on an adeno-associated virus vector delivered into the pancreatic duct and developed for Type 1 and Type 2 diabetes. It has formed wholly owned subsidiary Convergen Biotech to facilitate separation of the diabetes program; if that separation is completed, Convergen will focus on developing and commercializing GPX-002. Genprex is headquartered in Austin, Texas.

No enriched coverage for $GNPX in the last 7 days.

No SEC Form 4 filings for $GNPX in the last 30 days.

See all $GNPX insider activity →
Low

Genprex, Inc. issued a press release announcing results from a translational analysis of patients treated with its lead drug candidate, Reqorsa®…

Genprex, Inc. (GNPX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 5, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing results from a translational analysis of patients treated with its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product. The data

In 11 patients, gene therapy's early immune response partly faded as cell-maintenance signals rose

Genprex's REQORSA gene therapy showed a biphasic immune response in 11 lung cancer patients, shifting from an acute immune reaction to cellular maintenance pathways within 24 hours. The study linked TUSC2 to mitochondrial adaptation, autophagy, and protein quality control, supporting REQORSA's potential beyond oncology. Genprex is conducting further research with Meharry Medical College to explore broader biological activities of REQORSA.

Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress

Genprex (GNPX) presented data showing its gene therapy Reqorsa® activates cellular repair and maintenance programs linked to aging biology. The study found increased TUSC2 expression, delivered via Reqorsa, is associated with enhanced cellular resilience to aging-associated stress. Key findings include shifts in mitochondrial adaptation, autophagy, and protein quality control. The research was presented at the Gerontological Society of America's 2026 Annual Scientific Meeting.

GNPX sentiment & insider activity

Recent GNPX coverage spans financial news, technology and market movers.

What's driving GNPX

AlphAI scores every news story that mentions GNPX with an AI model for sentiment and relevance, and aggregates insider trades from Genprex, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GNPX

Score

Genprex, Inc. issued a press release announcing results from a translational analysis of patients treated with its lead drug candidate, Reqorsa®…

Genprex, Inc. (GNPX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 5, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing results from a translational analysis of patients treated with its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product. The data

In 11 patients, gene therapy's early immune response partly faded as cell-maintenance signals rose

Genprex's REQORSA gene therapy showed a biphasic immune response in 11 lung cancer patients, shifting from an acute immune reaction to cellular maintenance pathways within 24 hours. The study linked TUSC2 to mitochondrial adaptation, autophagy, and protein quality control, supporting REQORSA's potential beyond oncology. Genprex is conducting further research with Meharry Medical College to explore broader biological activities of REQORSA.

$GNPXLowClinical / regulatory

Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress

Genprex (GNPX) presented data showing its gene therapy Reqorsa® activates cellular repair and maintenance programs linked to aging biology. The study found increased TUSC2 expression, delivered via Reqorsa, is associated with enhanced cellular resilience to aging-associated stress. Key findings include shifts in mitochondrial adaptation, autophagy, and protein quality control. The research was presented at the Gerontological Society of America's 2026 Annual Scientific Meeting.

Genprex, Inc. issued a press release announcing that new research identifying TROP2 expression as a potential predictive biomarker of response to its lead…

Genprex, Inc. (GNPX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 4, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that new research identifying TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid)

Genprex highlights TUSC2 role in brain aging; mouse study shows sex-specific mitochondrial, proteostasis effects

Genprex reported peer-reviewed research showing TUSC2 loss disrupts mitochondrial function and protein homeostasis in mice, with stronger effects in males. The study, conducted by Meharry Medical College, links TUSC2 to aging-related decline in the hippocampus. Human data show TUSC2 decreases with age in most brain regions and is reduced in Alzheimer’s datasets. The findings expand understanding of TUSC2 beyond oncology. GNPX filed this information with the SEC.

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex (NASDAQ: GNPX) said it selected a U.S. CDMO to scale up manufacturing of its AAV-based diabetes gene therapy. The CDMO will produce cGMP drug product for IND-enabling preclinical studies and future clinical trials, including process optimization, scale-up, and analytical assay qualification. The program targets T1D and T2D.

Related tickers